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ABSTRACT
The transcription factor peroxisome proliferator-
activated receptor a (PPARa) is an important regu-
lator of hepatic lipid metabolism. While PPARa
is known to activate transcription of numerous
genes, no comprehensive picture of PPARa
binding to endogenous genes has yet been
reported. To fill this gap, we performed Chromatin
immunoprecipitation (ChIP)-chip in combination
with transcriptional profiling on HepG2 human
hepatoma cells treated with the PPARa agonist
GW7647. We found that GW7647 increased PPARa
binding to 4220 binding regions. GW7647-induced
binding regions showed a bias around the transcrip-
tion start site and most contained a predicted PPAR
binding motif. Several genes known to be regulated
by PPARa, such as ACOX1, SULT2A1, ACADL, CD36,
IGFBP1 and G0S2, showed GW7647-induced PPARa
binding to their promoter. A GW7647-induced
PPARa-binding region was also assigned to
SREBP-targets HMGCS1, HMGCR, FDFT1,
SC4MOL, and LPIN1, expression of which was
induced by GW7647, suggesting cross-talk
between PPARa and SREBP signaling. Our data fur-
thermore demonstrate interaction between PPARa
and STAT transcription factors in PPARa-mediated
transcriptional repression, and suggest interaction
between PPARa and TBP, and PPARa and C/EBPa
in PPARa-mediated transcriptional activation.
Overall, our analysis leads to important new
insights into the mechanisms and impact of
transcriptional regulation by PPARa in human liver
and highlight the importance of cross-talk with
other transcription factors.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors (TFs) that play an
important role in the regulation of numerous biological
processes, including lipid metabolism, adipocyte diﬀeren-
tiation, cell proliferation and inﬂammation (1). Three
diﬀerent highly conserved PPAR isotypes have been
identiﬁed: PPARa (NR1C1), PPARb/s (NR1C2) and
PPARg (NR1C3). The PPARa isotype has been shown
to govern expression of numerous genes involved in
fatty acid oxidation, ketogenesis, gluconeogenesis, choles-
terol catabolism and lipoprotein metabolism (2,3).
Additionally, PPARa has anti-inﬂammatory eﬀects by
suppressing pro-inﬂammatory genes (4,5). Consistent
with its prominent function in lipid metabolism, PPARa
is activated by various fatty acids and fatty acid derivates,
as well as by synthetic agonists such as fenoﬁbrate,
WY14,643 and GW7647 (6). Analogous to several other
nuclear receptors, PPARs form heterodimers with retinoid
X receptors (RXRs) (7), which occurs independently of
ligand or DNA binding (8). PPARs bind to DNA by
recognizing speciﬁc cis-acting PPAR responsive elements
(PPREs) present in the regulatory regions of PPAR target
genes. The consensus PPRE consists of a direct repeat of
the hexameric sequence AGGTCA separated by one less
conserved spacer nucleotide. PPARa was shown to bind
to the 50 motif of the PPRE, whereas RXR binds to the 30
motif (9). Full activation of gene transcription by the
DNA-bound PPAR–RXR complex is ultimately depen-
dent on the formation of a larger transcription initiation
protein complex via recruitment of a number of
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Additionally, PPARa has been shown to down-regulate
gene expression by interfering with the activity of other
TFs (11,12).
Recent studies using chromatin immunoprecipitation
(ChIP) in combination with genomic tilling microarrays
or sequencing (ChIP-chip or ChIP-Seq) have provided
important new information on the requirements for
DNA-binding by PPARs and other nuclear receptors.
One of the most interesting ﬁndings was that genes that
are activated by PPARg show an enrichment of modules
consisting of a PPRE-like motif together with a C/EBP
binding element (13,14). It was found that knocking-down
of either PPARg or C/EBP reduced expression of several
PPAR target genes, which was further reduced when these
genes where knocked down simultaneously (13). A similar
enrichment of a TF module was shown for the estrogen
receptor (ER), which clustered together with forkhead,
Oct1 and C/EBP motifs (15), as well as for the androgen
receptor (AR) and the glucocorticoid receptor (GR)
(16,17). These ChIP-chip studies thus reveal a complex
interplay between nuclear receptors and other TFs. This
cross-talk might be an important mechanism in gene reg-
ulation by nuclear receptors and may be responsible for
transcriptional regulation of speciﬁc sets of genes.
While several studies have mapped the genomic binding
regions of PPARg, there are no reports available that
describe the use of ChIP-chip or ChIP-Seq to investigate
genomic binding of PPARa. Accordingly, in the present
study we generated genome-wide maps of PPARa binding
regions in the HepG2 human hepatoma cell line using
ChIP combined with human promoter tiling arrays. We
used HepG2 cells because they represent the most widely
used cellular model for human liver cells, despite the
modest eﬀects of PPARa activation on gene expression.
Our analysis was targeted towards the discovery of
promoter sites showing increased PPARa binding in
response to PPARa activation by ligand. To investigate
the relation between promoter occupancy by PPARa and
regulation of gene expression, results of ChIP-chip
analysis were coupled to gene expression data.
MATERIALS AND METHODS
Cell culture
HepG2 cells were grown in phenol red-free Dulbecco’s
modiﬁed medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 2mM L-glutamine, 0.1mg/ml
streptomycin and 100U/ml penicillin. Cells were split the
day before experiments. Cells were kept at 37 C and 5%
CO2. The following day cells were treated with either
100nM of the PPARa agonist GW7647 or control
vehicle (DMSO). Cells used for ChIP-chip analysis were
harvested after 2h of GW7647 treatment. Cells used for
gene expression analysis were harvested after 6h of
GW7647 treatment.
ChIP
ChIP was performed as described previously (18). Brieﬂy,
protein–DNA complexes were cross-linked in 1%
formaldehyde for 10min at room temperature.
Cross-linking was stopped by addition of 1M glycine to
a ﬁnal concentration of 125mM for 5min. Cells were
washed twice with PBS, scraped and collected by
centrifugation. The cell pellet was dissolved in lysis
buﬀer (1% SDS, 10mM EDTA, 50mM Tris–HCl, pH
8.0). Extracts were sonicated using the Bioruptor
(Diagenode) at high power until DNA fragments of
 500–1000bp were formed. Sonicated chromatin was
diluted in ﬁve volumes of dilution buﬀer (0.01% SDS,
1.1% Triton X-100, 1.2mM EDTA, 167mM NaCl,
16.7mM Tris–HCl, pH 8.0). The immuno-complexes
were precipitated using antibodies against PPARa,
STAT1, STAT3 or STAT6 or normal serum IgG
(sc-9000, sc-592, sc-482, sc-981, sc-2027, Santa Cruz
Biotechnologies). Precipitated complexes were reverse
cross-linked and proteins digested with proteinase K
(Fermentas) overnight at 65 C. DNA fragments were
puriﬁed using the Aﬀymetrix GeneChIP Clean-up
module. Puriﬁed DNA was used for qPCR and
ChIP-chip analysis. ChIP experiments were run in
quadruplicate.
ChIP-chip
To obtain suﬃcient DNA for hybridization, puriﬁed ChIP
DNA was ampliﬁed and reampliﬁed with the WGA
(re)ampliﬁcation kit (Sigma-Aldrich). Ampliﬁed DNA
was fragmented with DNAse I to  50bp fragments. The
fragments were labeled with biotin according to
Aﬀymetrix instructions. Biotinylated DNA fragments
were hybridized to Human Promoter 1.0R Arrays
(Aﬀymetrix). Arrays were washed and scanned according
to instructions from manufacturer. Arrays were run in
quadruplicate for both untreated and GW7647 treated
cells.
Quantitative real-time PCR
Quantitative real-time PCR was performed on enriched
regions of LPIN1, HMGCR and AGPAT9. Equal
amounts of ampliﬁed ChIP material was used and mea-
surements were performed on the iCycler (BioRad) using
platinum Taq polymerase (Invitrogen) and the double
stranded DNA dye SYBR green. The following primers
where used: LPIN1: sense primer 50-ATTGGGGGTGTT
GTGGTATG-30 and anti-sense primer 50-ATAACAAAT
GCTGGCAAACG-30. AGPAT9: sense primer 50-CATCT
AATACACAAACCAAGG-30 and anti-sense primer 50-A
AGCCAAACAAAGACTATTCG-30. HMGCR: sense
primer 50-ACGCTGATTTGGGTCTATGG-30 and anti-
sense primer 50-GTGTAAATGGCTCCGGTCAC-30.
qPCRs were performed in duplicate and on all ChIP
samples used for ChIP-Chip. Other primer sequences are
available upon request.
Data analysis ChIP-chip
Aﬀymetrix microarray CEL ﬁles were acquired and
normalized using the Model-based analysis of tiling-arrays
(MAT) algorithm (19). MAT was also used to identify
PPARa binding regions induced by GW7647 treatment.
Tiling-array probe intensities from ChIP performed on
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with probe intensities from vehicle-treated HepG2 cells.
The analysis was performed with a MAT score of 2.4 or
higher, which was based on MAT scores found for pro-
moters of several known PPARa target genes. The human
NCBIv36 (hg18) was used as a mapping ﬁle. In our
analysis we used MaxGap of 400bp and a bandwidth
of 400bp.
Transcriptomics
Treatment of HepG2 cells with GW7647 for gene expres-
sion analysis by transcriptomics was performed in tripli-
cate. Total RNA was extracted from HepG2 cells with
TRIzol reagent (Invitrogen) and subsequently puriﬁed
using the SV Total RNA Isolation System (Promega).
RNA quality was measured on an Agilent 2100
bioanalyzer (Agilent Technologies) using 6000 Nano
Chips according to manufacturer’s instructions. RNA
was judged as suitable for array hybridization only when
samples showed intact bands corresponding to the 18S
and 28S rRNA subunits, displayed no chromosomal
peaks or RNA degradation products and had a RNA
integrity number above 8.0. Five micrograms of RNA
were used for one cycle cRNA synthesis (Aﬀymetrix).
Hybridization, washing and scanning of Aﬀymetrix
human genome 133 2.0 plus arrays was carried out
according to standard Aﬀymetrix protocols. Scans of the
Aﬀymetrix arrays were processed using packages from the
R/Bioconductor project. Arrays were normalized with
quantile normalization and expression levels of probe
sets were calculated using the robust multichip average
method. Diﬀerentially expressed probe sets were identiﬁed
using Limma and genes were considered to be signiﬁcantly
changed when raw q-value <0.05 and fold-change >1.2.
Genes regulated with a annotated ChIP-chip peak in its
promotor region are listed in Supplementary Table S1.
Characterization of PPARa binding regions
For annotation of the ChIP peaks to adjacent genes, we
used the Genomatix tool RegionMiner. The genes with
the shortest distance to the ChIP enriched binding site
were selected. For identiﬁcation of new TF modules the
software tool FrameWorker was used (20). GW7647-
induced PPARa binding regions that were assigned to
the top 25 diﬀerentially regulated genes (both up- and
down-regulated) were analyzed. The minimal occurrence
of a module in the binding regions studied was set at 20%
and a maximal distance bandwidth variation between the
motives was set at 75bp. Another Genomatix tool,
ModelInspector, was used to scan all the PPARa
binding regions linked to GW7647-regulated genes. As a
control, we scanned approximately all human promoter
regions present in the Genomatix promoter database
with sizes between 1 and 1.5kb, which corresponds with
the average size of the binding sites identiﬁed by
ChIP-chip. We used a two-proportion z-test to analyze
signiﬁcant enrichment of modules. Samples with p-values
values below 0.05 were considered signiﬁcantly diﬀerent.
Motif analysis
To investigate the presence of de novo DNA motifs,
the top 25 PPARa binding regions linked to up- or
down-regulated genes were loaded into the MEME
tool (http://meme.sdsc.edu/meme4_1/cgi-bin/meme.cgi).
The length for the output motif was varied between 12
and 20bp. Enriched matrixes of output motifs were
compared to existing motif matrixes available in both
the TRANSFAC and the JASPAR database with the
use of the STAMP tool (http://www.benoslab.pitt
.edu/stamp/index.php).
Data release
The ChIP-chip and expression array data have been sub-
mitted to GEO and the data will be released upon
publication.
RESULTS
Mapping of PPARa binding regions to adjacent
transcripts
PPARa represents a ligand-induced TF that in the absence
of ligand does not seem to act as transcriptional repressor,
unlike several other nuclear receptors (21). For the
analysis presented here we assumed that induction of
PPARa target gene expression by PPARa ligand is
associated with increased binding of PPARa to the
DNA, which is supported by ample experimental data
(22–27). Therefore, to identify the complete repertoire of
hepatic PPARa target genes, we treated HepG2 cells with
the synthetic ligand GW7647 for 2h and performed
ChIP-chip analysis using an antibody against PPARa,
with vehicle-treated HepG2 cells serving as control.
After ampliﬁcation and ﬂuorescent labeling, the immuno-
precipitated chromatin templates were hybridized to
Aﬀymetrix human promoter tiling arrays. These arrays
cover promoter regions of 7.5kb upstream and 2.5kb
downstream of the transcription start site (TSS).
Statistical analysis of four replicate experiments
provided evidence for increased binding of PPARa to
4220 binding regions in response to treatment with
GW7647.
We used the Genomatix tool RegionMiner to map the
genes closest to the 4220 GW7647-induced PPARa
binding regions in four genomic directions and selected
the gene with the shortest distance to the binding region.
The 4220 PPARa binding regions were linked to 3670
unique genes, of which 2875 were present on the expres-
sion arrays used for gene expression analysis. Analogous
to other nuclear receptors, PPARa binding regions
showed a bias towards the TSS (Figure 1A) (15,16,
28,29). To further analyze the location of PPARa
binding regions, the online tool PinkThing (http://
pinkthing.cmbi.ru.nl/cgi-bin/index50.pl) was used, which
categorizes binding regions based on distance relative to
the TSS (Figure 1B). We found that 46% of the binding
regions were located within introns, which matches very
well with a similar analysis done for PPARg (14). Since we
used promoter arrays, binding regions located to introns
Nucleic Acids Research,2010, Vol.38, No. 9 2841are in most cases present in the ﬁrst intron. It is possible
that some of these intronic binding regions actually
surround the TSS of an alternative splice variant of a
gene. Most other binding regions were identiﬁed
upstream of the TSS with 26% within 5kb and 11%
between 5 and 25kb. The more distal binding regions
are not covered by promoter tiling arrays and therefore
binding regions were not expected for the categories 30 far
(5–25kb) and distant (>25kb). Hence, the 1 and 2% of
binding regions located to the 30 far and distant categories,
respectively, likely reﬂect misclassiﬁcation by the
PinkThing tool.
Several genes that are established targets of PPARa,
such as SULT2A1, ACOX1, ACADL, CD36, IGFBP1
and G0S2 (18,27,30–34), showed GW7647-induced
PPARa binding regions in the promoter (Figure 1C).
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Figure 1. Mapping of PPARa binding regions enriched upon GW7647 treatment. (A) Positional distribution of all identiﬁed PPARa binding regions
relative to TSSs of the nearest gene. (B) Identiﬁcation of the genomic location of PPARa binding regions using PinkThing. The following classi-
ﬁcation criteria were used: distant (>25kb), 50 far (25–5kb), 50 near (5–0kb), intron (intronic), exon (exonic), 30 near (0–5kb) and 30 far (5–15kb).
(C) Enrichment of promoter regions in PPARa target genes. Enriched ChIP-chip signals were visualized using Aﬀymetrix integrated genome browser.
Coverage of promoter tiling array is indicated in red, repetitive sequences in black, and conserved sequence in blue. PPARa target genes SULT2A1,
ACOX1, IGFBP1, ACADL, CD36 and G0S2 all show positive enrichment within promoter regions. No enrichment is observed in the promoter of
ANGPTL4 as the known PPRE is present within the (non-covered) intron 3.
2842 Nucleic Acids Research, 2010,Vol.38, No. 9However, many other known PPARa target genes did not
show any ligand-induced binding regions in their
promoter. For these genes, PPARa is likely bound to a
binding site not covered by the promoter array or, less
likely, their PPRE may be located in repetitive sequences,
which are excluded from Aﬀymetrix human promoter
tiling arrays using RepeatMasker. For example, the
PPARa target gene ANGPTL4 carries a ligand-induced
PPARa binding site in the third intron (24), which is out
of the range of 2.5kb downstream of the TSS covered by
the array. As a result, no signiﬁcant peak is present within
the ANGPTL4 promoter (Figure 1C). Finally, it cannot be
excluded that for some PPAR targets the degree of
promoter occupancy by PPARa is not inﬂuenced by
PPARa agonist and therefore no signals are detected,
since our analysis concentrated on GW7647-induced
PPARa binding regions.
Overlap between ChIP-chip and expression array
To investigate the relation between genes assigned to a
GW7647-induced PPARa binding region and expression
of that particular gene, we performed expression
microarray analysis on HepG2 cells treated with
GW7647 for 6h. Conﬁrming activation of PPARa, estab-
lished PPARa targets CYP1A1, ADFP and TRIB3 were
signiﬁcantly induced by GW7647 (Figure 2A). Genes were
considered signiﬁcantly regulated if the mean fold change
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Figure 2. Overlap between GW7647-induced PPARa binding and GW7647-induced changes in expression. (A) Signiﬁcant induction of PPARa
targets by GW7647 treatment. (B) Number of genes signiﬁcantly altered upon GW7647 treatment as determined by microarray analysis using
criteria: fold change >1.2 and q-value <0.05. (C) Overlap between genes assigned to GW7647-induced PPARa binding regions and genes altered
after treatment with GW7647 as determined by transcriptomics. (D) Percentage of GW7647-induced PPARa binding regions linked to either up- or
down-regulated genes that contain at least one V$PERO site, as determined using Genomatix. Similar analysis was done for all GW7647-induced
PPARa binding regions as well as a control set of promoter regions in the Genomatix promoter database with similar size range as the binding
regions identiﬁed by ChIP-chip (1000–1500bp).
Nucleic Acids Research,2010, Vol.38, No. 9 2843exceeded 1.2 and q-value <0.05. The low cut-oﬀ for fold
change was used because the magnitude of induction of
PPARa target genes in HepG2 cells is limited. Using these
criteria 555 genes were diﬀerentially regulated after
6h GW7647 treatment (Figure 2B). Slightly more genes
were up-regulated than down-regulated. Diﬀerentially
regulated genes were compared with the genes assigned
to the GW7647-induced PPARa binding regions. It was
found that 54 genes up-regulated by 6h GW7647 treat-
ment were linked to at least one PPARa binding region,
representing 17.8% of all up-regulated genes (Figure 2C
and Supplementary Data). In comparison, 16.2% of all
genes on the expression array were linked to a PPARa
binding region, which indicates that genes up-regulated
by GW7647 showed minimal enrichment for PPARa
binding. Surprisingly, a PPARa binding region was also
linked to 46 genes down-regulated by 6h treatment with
GW7647, representing 18.3% of all down-regulated genes
(Figure 2C, Supplementary Data). Expression of the far
majority of genes assigned to a GW7647-induced PPARa
binding region was not altered by GW7647 treatment.
With the use of the Genomatix tool RegionMiner, the
PPARa binding regions linked to diﬀerentially expressed
genes were scanned for the presence of a V$PERO site,
which represents a PPRE matrix created by Genomatix
(20). At least one V$PERO site was present in 81 and
80% of the PPARa binding regions linked, respectively,
to the signiﬁcantly up- or down-regulated genes (Figure
2D). Similarly, 76% of all PPARa binding regions
identiﬁed by ChIP-chip contained a V$PERO site. In
contrast, only 66% of control promoter regions contained
a V$PERO site, for which we selected promoter regions in
the Genomatix promoter database with similar size range
as the binding regions identiﬁed by ChIP-chip (1000–
1500bp). These data suggest modest enrichment of
PPARa binding regions for PPREs predicted with the
V$PERO matrix.
Five genes out of 54 genes that were linked to a
GW7647-induced PPARa binding region (Figure 3A and
data not shown) and were up-regulated by GW7647
(Figure 3B) are direct target genes of the SREBP TFs:
HMGCS1, HMGCR, FDFT1, SC4MOL and LPIN1,
while AGPAT9 is a candidate target gene based on its
role in triacylglycerol synthesis. Enrichment by GW7647
treatment of PPARa binding regions linked to LPIN1,
AGPAT9 and HMGCR was conﬁrmed by normal ChIP
and qPCR (Figure 3C). As expression of several other
established SREBP target genes was also up-regulated
by GW7647 (Figure 3D) (35), these data suggest
possible cross-talk between PPARa and SREBP signaling.
Motifs and module searches
To search for speciﬁc DNA motifs in GW7647-induced
PPARa binding regions we performed a de novo motif
search with MEME (http://meme.sdsc.edu/meme4_1/cgi-
bin/meme.cgi). For this analysis we used the binding
regions of the 25 most signiﬁcantly up-regulated genes
that were assigned to a GW7647-induced PPARa
binding site (Figure 4). Identiﬁed motifs were compared
to the two major motif databases TRANSFAC and
JASPAR to search for similarities to existing TF binding
motifs using STAMP (http://www.benoslab.pitt.edu/
stamp/index.php). One of the identiﬁed motifs matched
the PPARa–RXRa motif in the TRANSFAC database.
While the classical AGGTCA motif of a PPRE was
present, a clear DR1-type tandem repeat was not found.
This is in line with the earlier ﬁndings indicating that the
PPRE 50 motif is less conserved than the 30 motif (14,36),
suggesting that the site we found is most likely a 30 motif.
A second motif had a similarity hit with the C/EBPa motif
in the JASPAR database, indicating that C/EBPa motif
is enriched in PPARa binding regions. Interestingly, the
C/EBPa motif was recently shown to be enriched in
PPARg binding regions and important for regulation of
PPARg target genes (13).
TFs often work in conjunction with other TFs to
regulate DNA transcription. Accordingly, we examined
whether other TF binding motifs are enriched together
with the PPAR binding motif within the set of
GW7647-induced PPARa binding regions linked to up-
or down-regulated genes, using the Genomatix tool
Frameworker. The PPAR matrix V$PERO was set and
screening was performed for binding motifs of other
TFs. Within the binding regions of the 25 most signiﬁ-
cantly up-regulated genes linked to a GW7647-induced
PPARa binding region, we identiﬁed a highly signiﬁcant
(p=6.94 10
 8) module composed of the TATA binding
protein (TBP, O$TBP) in combination with the PPAR
binding motif V$PERO (Figure 5A). Within the binding
regions of the 25 most signiﬁcantly down-regulated genes
linked to a GW7647-induced PPARa binding region, we
identiﬁed a highly signiﬁcant (p=1.04 10
 8) module
composed of the binding motif for the TF signal trans-
ducers and activators of transcription (STAT) family
(V$STAT) together with V$PERO (Figure 5A). To
further analyze for the presence of these speciﬁc modules,
we used ModelInspector to scan all the PPARa binding
regions linked to GW7647-regulated genes. As a control,
we also scanned all human promoter areas present in the
Genomatix promoter database with a size between 1 and
1.5kb. As shown in Figure 5B, the module STAT-PERO
is signiﬁcantly enriched in the binding regions linked to
genes that are down-regulated after 6h GW7647 treat-
ment compared to binding regions linked to genes
up-regulated by GW7647 treatment and to all human
promoter regions present in the Genomatix promoter
database. In fact, the STAT-PERO module was found in
eight out of 46 genes that were linked to a GW7647-
induced PPARa binding region and were down-regulated
by GW7647. Similarly, the TBP-PERO module is signi-
ﬁcantly enriched in binding regions linked to up-regulated
genes compared to binding regions linked to down-
regulated genes and all human promoter regions. These
results suggest interaction between PPARa and STAT in
PPARa-mediated transcriptional repression and interac-
tion between PPARa and TBP in PPARa-mediated
transcriptional activation.
Members of the STAT family bind to similar DNA
sequences. Expression proﬁling indicated that expression
of STAT3 was highest in HepG2 cells, followed by STAT1
and STAT6 (data not shown). Accordingly, we focused on
2844 Nucleic Acids Research, 2010,Vol.38, No. 9those three proteins to experimentally validate the sug-
gested interaction between PPARa and STATs on the
promoter of the aforementioned eight genes. HepG2
cells were treated with GW7647 for 2h and ChIP per-
formed using antibodies against STAT3, STAT1 and
STAT6 with vehicle-treated HepG2 cells serving as
control. Precipitated chromatin was subsequently
ampliﬁed using primers around the predicted
STAT-PERO site. Consistent with interaction between
PPARa and STATs, for seven out of eight genes STAT1
was released in response to GW7647 treatment (Figure 5C
and Supplementary Figure S1). A similar picture emerged
for STAT3. In contrast, STAT6 showed minor binding
which generally was not altered by GW7647. These
data show that PPARa activation and DNA binding
causes the release of STAT3 and STAT1 from gene pro-
moters concurrent with down-regulation of gene
expression.
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Figure 3. Cross-talk between PPARa- and SREBP-dependent gene-regulation. (A) Enriched ChIP-chip signals for HMGCS1, HMGCR, LPIN1 and
AGPAT9 genes were visualized using Aﬀymetrix integrated genome browser. Coverage of promoter tiling array is indicated in red, repetitive
sequences in black and conserved sequences in blue. (B) Gene expression changes after 6h PPARa agonist treatment of ﬁve direct SREBP target
genes and possible SREBP target gene AGPAT9. A GW7647-induced PPARa binding region was assigned to each of these genes. Signiﬁcant
diﬀerences are indicated with an asterisk (Student’s t-test, p<0.05). (C) Transcriptional up-regulation of selected SREBP1 target genes involved
in lipogenesis after 6h PPARa agonist treatment represented as a heat map. (D) Enriched DNA binding of PPARa to promoter regions of
LPIN1, AGPAT9 and HMGCR after 2h GW7647 treatment, veriﬁed by ChIP-qPCR using primers designed within the binding region found
by ChIP-Chip.
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Finally, within up-regulated genes that were assigned
to GW7647-induced PPARa binding regions we
analyzed for functional biological clusters using DAVID
(http://niaid.abcc.ncifcrf.gov/home.jsp). We found signiﬁ-
cant over-representation of genes in the biological cluster
of sterol and lipid biosynthetic process (Table 1), in line
with binding of PPARa to the putative promoter of
several SREBP targets. Within down-regulated genes
that were assigned to GW7647-induced PPARa binding
regions we found signiﬁcant over-representation of genes
in the biological cluster of humoral and innate immune
response, which is consistent with the known suppressive
eﬀect of PPARa on inﬂammation (Table 1).
DISCUSSION
It is well established that PPARa is a major
transcriptional regulator of fatty acid metabolism in
liver. Numerous genes involved in fatty acid oxidation
and other metabolic processes have been identiﬁed as
direct target genes of PPARa in mouse, characterized by
the presence of a functional PPRE (2,33). In the past few
years, genomic binding regions of several nuclear recep-
tors including PPARg have been mapped (13,14).
However, no reports are available that were aimed at
mapping the binding regions for PPARa. In our study
we used ChIP-chip to investigate ligand-induced PPARa
binding to genomic regions within HepG2 human
hepatoma cells.
A total number of 4220 ligand-induced PPARa binding
regions were identiﬁed, which were assigned to 3670
unique genes. Although this number may appear excep-
tionally high, the threshold for inclusion was set based on
inspection of a number of known PPARa binding regions.
Our assignment of PPARa binding regions relative to the
nearest gene showed a distance-to-TSS distribution
centered around the TSS. Categorizing these distances
revealed that the majority of the binding regions are
located within an intron or in the 50 proximal region.
These ﬁndings are in line with various studies showing
that TF binding regions are normally distributed around
the TSS (29,37–39). The preponderance of binding regions
around the TSS may also reﬂect DNA looping allowing
nuclear receptors bound to distal sites to contact the basal
transcription machinery. Previous genome-wide analysis
of ERa and PPARg binding sites indicate that a large
fraction of the binding regions are located distal from
the TSS (13,15). Since we used promoter tiling arrays,
our analysis was unable to detect binding to distant
binding regions. Some of these distal elements have
been shown to indeed function as functional PPREs
(24,40–42). However, many distant binding regions
are likely misclassiﬁed and are actually located in
proximal promoters of new transcripts (43,44).
Furthermore, many regions identiﬁed by ChIP-based
methods do not show any eﬀect on the expression of the
gene closest to that region. These issues raise questions
about the functional relevance of many of these binding
regions (45).
We compared our ChIP-chip data with mRNA expres-
sion data collected by expression microarray and found
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Figure 4. De novo motif analysis. GW7647-induced PPARa binding regions were screened for speciﬁc DNA motifs via de novo motif search using
MEME. The binding regions of the 25 most signiﬁcantly up-regulated genes assigned to GW7647-induced PPARa binding regions were analyzed.
Signiﬁcantly enriched motifs were compared with motif databases TRANSFAC as well as JASPAR with the use of STAMP. Similarity scores with
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2846 Nucleic Acids Research, 2010,Vol.38, No. 9that  18% of the genes induced by ligand were linked to a
GW7647-induced PPARa binding region. The other 82%
may not represent direct target genes, may bind PPARa
equally in absence and presence of ligand, may bind
PPARa via a site located outside the range covered by
the array, or the actual PPARa binding region was
linked to a diﬀerent gene.
Importantly, the overwhelming majority of PPARa
binding regions were linked to genes that were not
signiﬁcantly altered upon GW7647 treatment, even after
more prolonged treatment (data not shown). It is well
recognized that the majority of binding regions found by
ChIP-chip or ChIP-Seq experiments do not have any eﬀect
on the genes they were linked to (45). This could be par-
tially due to miss-annotation, which is inevitable when
assigning to the nearest gene. However, since the
number of GW7647-induced binding regions far exceeds
the number of GW7647-regulated genes many regions
must bind PPARa without any impact on gene regulation.
These ﬁndings are consistent with the ‘scanning model’
proposed for PPARs, which states that PPARs scan the
genome and transiently bind to PPRE-like sequences
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Figure 5. Enrichment of TF modules in PPARa binding regions. (A) The binding regions of the 25 most signiﬁcantly up-regulated genes assigned to
GW7647-induced PPARa binding regions were analyzed for TF modules using the Genomatix tool Frameworker. Two modules were identiﬁed:
TBP-PERO and STAT-PERO in the binding regions linked to up- or down-regulated genes, respectively. (B) The modules TBP-PERO and
STAT-PERO were scanned for the relative presence in all GW7647-induced PPARa binding regions located near transcriptional regulated as
well as all human promoter regions present in the Genomatix database. A two-proportion z-test was used to analyze signiﬁcant enrichment of
modules. p-values values below 0.05 were considered signiﬁcantly diﬀerent. (C) Loss of DNA binding by STAT3 and STAT1 upon PPARa acti-
vation. HepG2 cells were treated with GW7647 for 2h and ChIP performed using antibodies against STAT3, STAT1 and STAT6 with
vehicle-treated HepG2 cells serving as control. Precipitated chromatin was subsequently ampliﬁed using primers around the predicted
STAT-PERO site found in four genes that were linked to a GW7647-induced PPARa binding region and were down-regulated by GW7647.
Signiﬁcant diﬀerences are indicated with an asterisk (Student’s t-test, p<0.05).
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model, PPARs only start transcription upon binding to
a bona ﬁde PPRE (10). What distinguishes a bona ﬁde
PPRE from a PPRE-like sequence is not well understood.
Recent ChIP-chip studies on several TFs revealed that
clusters of diﬀerent TF binding elements are enriched in
proximity of the binding region for the TF under study
(13,15,16,46–48). We searched for these types of clusters in
PPARa binding regions that were linked to diﬀerentially
regulated genes and found several modules of TF binding
elements in combination with a PPRE. In PPARa binding
regions linked to up-regulated genes we found enrichment
for a module composed of the binding sequence for TBP
together with that of PPARa. Since TBP is an important
component of the basal transcriptional machinery, this
ﬁnding suggests binding of PPARa adjacent to the core
promoter. A second interesting module we found was a
combination of a PPARa binding sequence and a STAT
binding sequence, which was strongly enriched in PPARa
binding regions linked to genes that were down-regulated
by PPARa activation. STAT TFs function downstream in
the signaling pathway of a large number of cytokines,
growth factors and hormones (49). Follow-up analysis
by normal ChIP showed that binding of STAT3 and
also STAT1 to these genes was reduced upon GW7647
treatment. Our data suggest that loss of STAT binding
is dependent on binding of PPARa adjacent to the
STAT binding site. Inhibition of STAT-dependent
transcriptional activity and DNA binding has been
previously documented for PPARg and PPARb/s
(50–54), and may also partially account for the anti-
inﬂammatory action of PPARa activation (17). Overall,
down-regulation of gene expression by PPARa activation
in HepG2 cells may be partially mediated by interfering
with binding of STAT3 and STAT1 to the DNA.
Using Genomatix we found that at least one V$PERO
site was present in 81% of the PPARa binding regions
linked to the signiﬁcantly up-regulated genes. A similarly
high percentage was found for all the GW7647-induced
PPARa binding regions resulting from the ChIP-chip
analysis. While this result would suggest that the
majority of PPAR binding detected by our ChIP-
chip analysis conforms to the general paradigm of
PPRE-dependent DNA binding, it should be emphasized
that V$PERO sites are found at relatively high frequency
throughout the genome and may have limited speciﬁcity.
As ChIP is capable of detecting any type of binding of
PPARa to DNA, which includes indirect binding via
other TFs, it is diﬃcult to provide a good estimate of
the relative importance of PPRE-dependent and -indepen-
dent binding to DNA. Binding to DNA of TFs in the
absence of a consensus motif has been a common obser-
vation in recent ChIP-chip and ChIP-seq studies. Several
explanation may account for this apparent discrepancy as
elaborated by Farnham (45), including binding at a distal
site that contains a consensus motif and looping to the site
in question through protein–protein interactions; ‘piggy-
back’ binding that is mediated by protein–protein interac-
tions with a second factor and that does not involve the
DNA binding domain of the ﬁrst factor; or assisted
binding to a site that is similar to the consensus site,
which is enhanced by protein–protein interaction with
another site speciﬁc DNA binding factor or with a specif-
ically modiﬁed histone.
Within the set of GW7647-induced PPARa binding
regions linked to up-regulated genes, no established
direct PPARa targets were present. One problem is that
HepG2 cells, despite their broad use, poorly reﬂect gene
regulation by PPARa in other cultured cells such as rat
FAO hepatoma cells (55) and primary human
hepatocytes. Indeed, we found remarkably little overlap
in gene regulation by PPARa agonist between HepG2
cells and primary human hepatocytes (van der Meer
et al., manuscript in preparation). Unfortunately,
ChIP-chip analysis in primary human hepatocytes is prac-
tically unfeasible. Clearly, an ideal system to study
PPARa-dependent gene regulation in human is lacking.
The TFs SREBP-1 and SREBP-2 are important regula-
tors of hepatic lipid and cholesterol synthesis (56).
Previously, it was shown that PPARa is involved in the
normal circadian regulation of target genes of SREBPs,
including HMGCR (57). Furthermore, synthetic PPARa
agonists were found to induce expression of SREBP
targets in liver, which was completely abolished in
SREBP-1
 /  mice and PPARa
 /  mice (58,59). The
eﬀect of PPARa agonists on SREBP targets was
attributed to increased activation of SREBP-1c via
enhanced proteolytic cleavage, and was not mediated by
changes in SREBP-1 mRNA (58). In the present article,
we ﬁnd induction of expression of several SREBP targets
by PPARa activation in human hepatoma HepG2 cells.
Furthermore, in these cells PPARa agonist stimulated
binding of PPARa to the putative promoter of SREBP
targets HMGCS1, HMGCR, FDFT1, SC4MOL and
LPIN1 genes. These data suggest important cross-talk
between PPARa and SREBP signaling. The exact nature
of the cross-talk requires further investigation but one
possibility is that PPARa is recruited to promoters of
SREBP targets via direct physical interaction with
SREBP. It could be envisioned that through this interac-
tion PPARa may promote SREBP activity, perhaps by
assisting with recruitment of transcriptional co-activators.
In addition to the above-mentioned genes, a PPARa
binding region was assigned to the AGPAT9 gene, which
can be suspected to be a SREBP target as well. LPIN1 and
AGPAT9 encode enzymes that catalyze the second and
Table 1. Enrichment of biological processes in GW7647-regulated
genes assigned to a PPARa binding region
Biological process p-value
Up-regulated genes
Sterol biosynthetic process 1.1E-4
Apoptosis 1.9E-2
Developmental process 2.2E-2
Lipid biosynthetic process 4.0E-2
Down regulated genes
g-Hexachlorocyclohexane 1.8E-3
Humoral immune response 1.2E-2
Up-regulated genes assigned to GW7647-induced PPARa binding
regions were analyzed for functional biological clusters using DAVID.
2848 Nucleic Acids Research, 2010,Vol.38, No. 9third step in the triacylglycerol synthesis pathway. So far,
several genes involved in either fatty acid or triacylglycerol
synthesis have been identiﬁed as direct PPARa target
genes including 5 and 6 desaturases and malic
enzyme [summarized in refs (2,3)]. Indeed, the
involvement of PPARa in lipogenesis appears to be
much more extensive that previously understood (60).
Although this notion is seemingly at odds with increased
hepatic TG observed upon PPARa deletion, regulation of
fatty acid metabolism by PPARa is probably more subtle
than generally envisioned. According to data presented
here, PPARa may also indirectly impact lipid biosynthesis
via cross-talk with SREBP.
In aggregate, it can be concluded that ChIP-chip repre-
sents a powerful tool to investigate whole genome binding
of PPARa. Our data indicate that PPARa agonists trigger
the binding of PPARa to a large number of genomic sites
and provide novel insights into the mechanisms of
PPARa-dependent transcriptional regulation.
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